Impact Biomedical (IBO) Total Liabilities (2022 - 2026)

Impact Biomedical's Total Liabilities history runs 5 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• Quarterly Total Liabilities fell 82.06% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 82.06% YoY) and the FY2025 annual result came in at $1.8 million, down 85.83% from the prior year.
• Total Liabilities was $2.4 million for Q1 2026 at Impact Biomedical, up from $1.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $44.4 million in Q1 2024 and bottomed at $1.8 million in Q4 2025.
• A 5-year average of $18.9 million and a median of $15.3 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 188.53% — and 2025, when it slumped 85.83%.
• Impact Biomedical's Total Liabilities stood at $13.8 million in 2022, then grew by 18.39% to $16.4 million in 2023, then declined by 20.27% to $13.1 million in 2024, then slumped by 85.83% to $1.8 million in 2025, then increased by 28.38% to $2.4 million in 2026.
• Business Quant data shows IBO's Total Liabilities at $2.4 million in Q1 2026, $1.8 million in Q4 2025, and $27.1 million in Q3 2025.